With the takeover plans moving full steam ahead, medical device maker Boston Scientific Corp. has voluntarily withdrawn and refiled an antitrust notification regarding its $27 billion bid for heart device maker Guidant Corp.
Australian biotechnology company Novogen Research Party Ltd. has slammed Chattem Inc. with a lawsuit, accusing the health manufacturer of infringing on a patented method used to treat breast cancer, pre-menstrual syndrome and menopause.
Hoping to attend to the complex legal needs of the booming biotechnology and life sciences industries in and around Silicon Valley, Latham & Watkins has injected a new key player into its corporate department.
Botox manufacturer Allergan Inc. and Alcon Inc. have amicably ended a patent infringement battle that has lasted nearly two years over Alcon’s brimonidine 0.15% eye drops product.
U.S. Pharmaceutical giant Pfizer Inc. is taking on the Philippines to protect patents that cover its second best-selling drug Norvasc, only one month after a sweeping victory in U.S. courts cleared generic opposition.
In a move to fend off a rival’s attempts to produce and market a generic form of Nexium, AstraZeneca AB has fired off a lawsuit against drug maker IVAX Corporation for allegedly infringing on patents related to its widely prescribed ulcer drug.
After emerging from Chapter 11 bankruptcy protection, pharmaceutical firm AAIPharma Inc. has hit a roadblock, with the company it sold a major unit to now accusing it in court of failing to follow through on the sale.
Swiss drug maker F. Hoffmann-La Roche has become the first pharmaceutical company in India to win a product patent under the country’s new patent regime, receiving approval for its hepatitis C drug Pegasys.
Proposed legislation on Capitol Hill would raise the stakes in disputes between the pharmaceutical industry and generic drug manufacturers, with approval sure to reduce court-approved delays that keep generics off the market while being litigated.
The European Commission has initiated an antitrust investigation into medical device maker Boston Scientific Corp.’s $27-billion takeover bid for heart device maker Guidant Corp.
Although Medtronic Vascular, Inc. has been unsuccessful in the past to pin down infringement charges on Boston Scientific Corp., it took another swipe in its latest court filing March 1, hoping that this time the accusations will stick.
The U.S. Court of Appeals for the Federal Circuit has ruled that a case over stent patents should have been filed in Germany, upholding a lower court ruling that deflated the suit brought by a doctor against device makers Pfizer and Boston Scientific.
Foley & Larder LLP doesn’t rely on its IP laurels to attract customers and maintain its edge. The firm’s IP practice is highly active in shaping policy and applies significant resources to keep its clients—and industry in general—informed about the latest trends and their potential impact on commerce.
Johnson & Johnson subsidiary Alza Corporation has been smacked with a class-action antitrust lawsuit, accusing the unit of illegally trying to keep generic versions of overactive bladder drug Ditropan XL off the shelf.
In a move that promises to shield ABB Ltd. from future asbestos litigation troubles, a bankruptcy court has approved the amended reorganization plan of the Swiss/Swedish engineering group’s U.S. subsidiary, Combustion Engineering.
Sanofi-Aventis’ battle with generic drug makers over its popular allergy medicine Allegra is raging on, with the French pharmaceutical giant slapping generic manufacturer Ranbaxy with a patent infringement lawsuit.
In agreeing to hear the case between MedImmune and Genentech, the U.S. Supreme Court will set a precedent for whether licensees in good standing are permitted to challenge licensed patents.
A federal judge has ordered barcode equipment maker Metrologic Instruments Inc. to pay a $13.4 million arbitration award to its rival after it allegedly failed to pay royalties on a patent license agreement.
A government service cooperative has charged AstraZeneca with violating U.S. competition law, the latest swipe in a string of suits filed by nearly a dozen unions, pension funds and government agencies accusing the pharmaceutical giant of illegally trying to prevent generic versions of its blockbuster heart drug, Toprol-XL, from entering the marketplace.
Able Laboratories Inc., the former pharmaceutical developer that sold off its assets to India's Sun Pharmaceutical Industries Ltd. last year, is pursuing a Chapter 11 plan designed to pay back unsecured creditors roughly 27% on their claims.